MCG Post Myocardial Infarction Study

Last updated: December 19, 2018
Sponsor: Creavo Medical Technologies Ltd
Overall Status: Completed

Phase

N/A

Condition

Circulation Disorders

Congestive Heart Failure

Angina

Treatment

N/A

Clinical Study ID

NCT03358368
CIP 004
  • Ages > 18
  • All Genders

Study Summary

The study is being performed to evaluate a new portable medical device, the Creavo Vitalscan Magnetocardiograph (Vitalscan) on patients who have had a confirmed myocardial infarction (heart attack) within the previous 12 weeks.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients with confirmed myocardial infarction within 12 weeks of the initial event

  • Patients admitted to the Coronary Care Unit (CCU) at Warwick Hospital on the point ofdischarge or patients already discharged from the CCU attending the cardiacrehabilitation classes

  • 18+ year old male or female

  • Patient is willing and able to give written informed consent

Exclusion

Exclusion Criteria:

  • Atrial fibrillation

  • Thoracic metal implants (cardiac stents allowed)

  • Pacemaker or internal defibrillator

  • Pregnancy (if after 20-week period)* or lactation

  • Patient unable to lie down (i.e. supine position up to a maximum 25 degree tilt) orstay still on the examination bed

  • Patient unable to understand the informed consent process and/or has a poorunderstanding of English (e.g. English-speaking relative/translator not available)

  • There should not be any effect on pregnancy due to the non-invasive nature of thedevice. Pregnancy after the 20-week period excluded from the study due to thesize and position of the foetus and unknown possibility of picking up the foetalheartbeat, rendering the scan non-usable for study requirements

Study Design

Total Participants: 50
Study Start date:
March 22, 2018
Estimated Completion Date:
August 10, 2018

Study Description

Magnetocardiography (MCG) is a non-contact, passive, imaging technique that detects the magnetic fields generated by the electrical activity of the heart. The MCG technology has been evaluated in several clinical studies, demonstrating its potential usefulness in the detection of patients with stable angina and acute coronary syndrome (ACS), including non-ST segment elevation myocardial infarction (NSTEMI).

Previous studies have been completed using earlier versions of the Vitalscan device. Results showed that the device could differentiate between patients with confirmed ischaemic heart disease (IHD) and NSTEMI, those with non-IHD experiencing chest pain and healthy (non-ischaemic) control subjects.

The aim of this pilot study is to assess the difference between abnormal MCG images from patients with a confirmed and recent myocardial infarction (MI)and normal images from previously obtained healthy volunteer controls scanned with the current device, so that comparisons can be made to the data acquired from the previous studies.

Connect with a study center

  • South Warwickshire NHS Trust

    Warwick, Warwickshire CV34 5BW
    United Kingdom

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.